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BRIEF SUMMARY 
Hypertension in pregnancy is common, affecting approximately 7% of pregnancies in Canada. In 
this first Hypertension Canada Guidelines for hypertension in pregnancy, seven 
recommendations are presented. For non-severe hypertension in pregnancy (systolic BP 140-159 
and/or diastolic BP 90-109 mmHg), we provide guidance for the threshold for initiating 
antihypertensive therapy, blood pressure targets, as well as first- and second-line 
antihypertensive medications. Severe hypertension (systolic BP ≥160 and/or diastolic BP ≥110 
mmHg) requires urgent antihypertensive therapy.  
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ABSTRACT 
 We present Hypertension Canada's inaugural evidence-based Canadian recommendations 
for the management of hypertension in pregnancy. Hypertension in pregnancy is common, 
affecting approximately 7% of pregnancies in Canada, and requires effective management in 
order to reduce maternal, fetal and newborn complications. Given this importance, these 
guidelines were developed in partnership with the Society of Obstetricians and Gynaecologists of 
Canada with the main common objective of improving the management of women with 
hypertension in pregnancy. Guidelines for the diagnosis, assessment, prevention and treatment of 
hypertension in adults and children are published separately. 
In this first Hypertension Canada Guidelines for hypertension in pregnancy, seven 
recommendations for the management of non-severe and severe hypertension in pregnancy are 
presented.  For non-severe hypertension in pregnancy (systolic blood pressure 140-159 mm Hg 
and/or diastolic blood pressure 80-109 mm Hg), we provide guidance for the threshold for 
initiation of antihypertensive therapy, blood pressure targets, as well as first- and second-line 
antihypertensive medications. Severe hypertension (systolic blood pressure ≥160 mm Hg and/or 
diastolic blood pressure ≥110 mm Hg) requires urgent antihypertensive therapy to reduce 
maternal, fetal and newborn adverse outcomes. The specific evidence and rationale underlying 
each of these guidelines are discussed.  
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Introduction 
Hypertensive disorders of pregnancy (HDP) occur in approximately 7% of all 
pregnancies in Canada.1 HDP represent a broad range of conditions including:  chronic 
hypertension (i.e., pre-existing hypertension), gestational hypertension (i.e., hypertension that 
develops after 20 weeks gestation), and/or preeclampsia/eclampsia (gestational hypertension 
with proteinuria and/or other target organ involvement).2 HDP have a major impact on maternal, 
fetal and newborn outcomes including: fetal growth restriction, preterm delivery and fetal and 
neonatal morbidity and mortality. 2  After pregnancy, emerging evidence demonstrates that 
women with HDP represent a high-risk population for the development of cardiovascular risk 
factors (hypertension, type 2 diabetes and obesity), chronic kidney disease, premature 
cardiovascular disease (cardiac, cerebrovascular, and peripheral arterial) and cardiovascular 
mortality.4-7  Notably, HDP are an independent risk factor for cardiovascular disease associated 
with gradually elevated risk of cardiovascular disease with increasing severity of HDP from 1.7 
(adjusted hazard ratio [aHR]; 95% confidence interval [CI] 1.3 to 2.2) in women with gestational 
hypertension to 4.4 (aHR; 95% CI 2.4 to 7.9) in women with severe preeclampsia with fetal 
death.5, 8  
As HDP are prevalent and have important short- and long-term health impacts, 
Hypertension Canada’s target audience expressed a need for guidance on the management of 
hypertension in pregnancy.  In response, a Pregnancy Subgroup was formed in 2014 to develop 
evidence-based blood pressure (BP) management guidelines for pregnancy. A formal partnership 
was then established between Hypertension Canada and the Society of Obstetricians and 
Gynaecologists of Canada (SOGC) to ensure harmonization of guidelines through shared 
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guideline development as well as for broader reach of the guidelines through knowledge 
translation and dissemination strategies.   
These inaugural Hypertension Canada Guidelines for hypertension in pregnancy are 
intended to provide a framework for evidence-based care of hypertension in pregnancy but 
should not replace clinical judgement.  Practitioners are advised to consider patient preferences, 
values, and clinical circumstances when determining how to best apply these guidelines to 
individual patients.    
 
Methods 
  The Hypertension Canada Guidelines are developed annually through a highly structured 
and systematic process designed to minimize bias. Hypertension Canada’s guideline process has 
been externally reviewed and is in concordance with the Appraisal of Guidelines for Research 
and Evaluation II (AGREE II) Instrument for guideline development 
(guidelines.hypertension.ca/about/overview-process).9  The Hypertension Canada Guidelines 
Committee (HCGC) is comprised of a multidisciplinary panel of both content and 
methodological experts divided into 16 subgroups distinct areas of hypertension (Supplemental 
Appendix S1 and S2 for list of members and conflicts of interest).  The Pregnancy Subgroup 
consisted of eight members with a broad range of expertise, including internal medicine 
subspecialties as well as obstetrics (two members from the SOGC Maternal Fetal Medicine 
subcommittee).    
The comprehensive literature search was performed by a highly-trained medical librarian 
based upon key words and terms provided by the subgroup.  The initial literature search was 
performed in June 2015 and updated in June 2016 (details of search strategies and retrieved 
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articles are available upon request).  The literature was reviewed and graded using the 
standardized method developed by Hypertension Canada (Supplemental Table S1)  and 
according to the Hypertension Canada Guidelines established process.10  
The proposed pregnancy guidelines were then reviewed and modified by the Central 
Review Committee, unbiased experts in clinical epidemiology, to ensure that the guidelines 
reflected the evidence and verify proposed grading. The draft guidelines and supporting evidence 
were presented to the HCGC in Toronto, on October 12, 2017.  Following the discussions, the 
guidelines were further revised and finalized for an electronic vote by all 81 members of the 
HCGC, with greater than 70% support required for approval of each new/revised guideline. 
 
Challenges in pregnancy research 
There are several methodologic challenges in the obstetrical research related to BP that 
were taken into consideration during the Hypertension in Pregnancy Guidelines development 
process (Table 1). First, the definition of hypertension in pregnancy has changed over time.11 
Older studies included pregnant women with a DBP ≥90 mm Hg, whereas more recent studies 
have included women with a SBP ≥140 mm Hg or a DBP ≥90 mm Hg. Similarly, the definition 
of severe hypertension in pregnancy was reduced from ≥170/110 mmHg to ≥160/110 mm Hg 
after the association of stroke in pregnancy with a lower BP level.12 Second, as outlined above, 
the HDP represent a broad range of conditions with differing underlying pathophysiologies. 
Thus, the clinical outcomes (e.g., the neonate’s birth weight) may be a result of the underlying 
process (i.e., maternal endothelial dysfunction) and not solely the maternal BP values. Further, 
there is a lack of consensus on the definition of preeclampsia ranging from a restrictive definition 
(gestational hypertension plus proteinuria) to a broader definition (gestational hypertension plus 
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either proteinuria or ≥1 relevant target organ complication).11 This heterogeneity may influence 
clinical outcomes and as such it was taken into consideration when examining the findings of the 
studies. Third, the duration of antihypertensive treatment in pregnancy is relatively short (often a 
few weeks to months) when compared with studies of hypertension in non-pregnant population. 
Fourth, the clinical outcomes in studies of hypertension in pregnancy are generally not hard 
cardiovascular outcomes (i.e., cardiovascular events or cardiovascular mortality) which are 
associated with higher grades in the Hypertension Canada grading system (Supplemental Table 
S1).10 Studies of hypertension in pregnancy use other clinical outcomes (e.g., severe 
hypertension ≥160/110 mm Hg, preterm birth, etc.). While severe hypertension is considered a 
validated surrogate outcome due to its relationship with adverse maternal, fetal and newborn 
outcomes, it is associated with a lower grade of evidence.13  Finally, the sample size of studies of 
hypertension in pregnancy are generally small and, therefore, this limits accurate assessment of 
rates of adverse events associated with individual antihypertensive medications. 
 
Hypertension Canada’s 2018 Guidelines:  Management of Hypertension in Pregnancy 
Measuremenent  and diagnosis. Accurate BP measurement is essential to appropriately 
recognize and treat HDP. Detailed information on BP measurement as well as the classification 
and definitions of the HDP, are presented in SOGC’s 2014 Guideline “Diagnosis, evaluation and 
management of the hypertensive disorders of pregnancy”.2  In brief, women should have their BP 
measured using a standardized protocol after a period of rest in a quiet environment, be in sitting 
position with their arm at the level of the heart using an appropriately sized cuff (i.e., length 1.5 
times the circumference of the arm).2  The arm with higher BP values should be used for 
hypertension diagnosis and BP monitoring.2  Non-severe elevated BP should be re-measured  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
9 
 
again at the same visit, with at least a gap of 15 minutes from the first measurement. Over 50% 
of women with a first BP reading of  ≥140/90 mm Hg have white coat effect.14-16 Hypertension 
in pregnancy is defined as a systolic BP (SBP) ≥140 mm Hg and/or a diastolic BP (DBP) ≥90 
mm Hg (average of at least 2 measurements taken at least 15 minutes apart). Severity of 
hypertension in pregnancy is considered based upon both the presence of target organ 
involvement (i.e., maternal or the fetus itself) as well as the actual BP level. BP levels between 
140/90 mm Hg and <160/110 mm Hg are considered as non-severe hypertension in pregnancy. A 
BP level  of ≥160/110 mm Hg is associated with increased risk of maternal stroke in pregnancy 
and is therefore considered the diagnostic threshold of severe hypertension in pregnancy.2, 17  
Classifcation of HDP are summarized in Figure 1. 
 
I.  Management of non-severe hypertension (BP 140-159/90-109 mm Hg) in pregnancy 
Background.  HDP treatment of non-severe hypertension in pregnancy is important to reduce 
maternal, fetal and newborn complications including:  pregnancy loss, need for high-level 
neonatal care, preterm birth, and low birth weight.13, 18  In a 2014 Cochrane Collaborative 
systematic review, antihypertensive medication use for non-severe hypertension in pregnancy 
(49 randomized trials; n=4,723)19 was associated with a halving in the risk of progression to 
severe hypertension (relative risk [RR], 0.49; 95% CI 0.40 to 0.60). The number needed to treat 
was 10 (95% CI 8 to 13). This finding was consistent across all HDP range of conditions.19 
There was no consistent statistically significant reduction in other clinically important maternal, 
fetal or newborn outcomes.19 While this Cochrane systematic review was methodologically 
strong, the primary studies were relatively old (only 4 after 2001), had small sample sizes, and 
were of low methodologic quality.19  
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 The international multicentre randomized controlled trial, Control of Hypertension in 
Pregnancy Study (CHIPS), examined the effects of maternal BP targets on perinatal and 
maternal outcomes.18 Pregnant women with non-severe gestational hypertension or chronic 
hypertension were randomized to either less-tight BP control (target DBP of 100 mm Hg) or 
tight BP control (target DBP of 85 mm Hg).18  The CHIPS trial found an increase in the 
incidence of severe hypertension (defined as ≥160/110 mm Hg) in the less-tight group (RR 1.8; 
95% CI 1.34 to 2.28).18  In post-hoc analyses of the CHIPS trial, the occurrence of severe 
hypertension was associated with an increased risk of pregnancy loss, the need for high-level 
neonatal care >48 hours, low birth weight, and preterm delivery.13  
 In considering specific antihypertensive agents for the management of non-severe 
hypertension in pregnancy, the above Cochrane systematic review demonstrated a similar benefit 
in reduction of severe hypertension amongst the following oral agents: labetalol, methyldopa, 
long-acting nifedipine, or other β-blockers (Table 2).19  Additionally, a secondary analysis of the 
CHIPS trial showed no statistically significant difference in clinical outcomes between different 
anti-hypertensive medications used (i.e., labetolol, methyldopa, or others).20  Other oral 
antihypertensive medications such as clonidine, hydralazine, and thiazide diuretics can be 
considered as second-line drugs as they have not been associated with congenital malformations 
or other evidence to suggest harms. Angiotensin converting enzyme (ACE) inhibitors have not 
been consistently associated with congenital malformations but are associated with fetotoxic 
adverse effects to the developing fetal renal system (i.e., acute kidney injury and 
oligohydraminos) and, as such, should be avoided in pregnancy.21  Similarly, angiotension 
receptor blockers (ARBs) have limited published safety data in pregnancy and should be avoided 
in pregnancy due to similar fetotoxic mechanisms associated with ACE inhibitors.2   
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Overall, decisions regarding specific antihypertensive drug must consider the context of 
the patient and fetus, medication side-effect profile (including maternal hypotension), availability 
of medications, clinician experience and a woman’s preference.  Other components of the 
management of women with non-severe hypertension in pregnancy are beyond the scope of this 
guideline.  The involvement of an interdisciplinary team of care providers (i.e., obstetrics, 
maternal fetal medicine and medical specialists as appropriate) is prudent to ensure the ongoing 
well-being of the mother and fetus through frequent assessments, monitoring, and delivery 
planning, as indicated (Figure 2).2 
 
Guidelines 
1.  Antihypertensive therapy is recommended for average SBP measurements of ≥140 mm Hg or 
DBP measurements of ≥90 mm Hg in pregnant women with chronic hypertension, gestational 
hypertension or preeclampsia (Grade C).  
2. A.  Initial antihypertensive therapy should be monotherapy from the following first-line drugs:  
oral labetalol, oral methyldopa, long-acting oral nifedipine, or other oral β-blockers (acebutolol, 
metoprolol, pindolol, and propranolol) (Grade C). 
2. B. Other antihypertensive drugs can be considered as second-line drugs including: clonidine, 
hydralazine, and thiazide diuretics (Grade D). 
2. C. ACE inhibitors (Grade C) and ARBs (Grade D) should not be used in women once 
pregnant. 
3. A.  A DBP of 85 mm Hg should be targeted for pregnant women on antihypertensive therapy 
with chronic hypertension or gestational hypertension (Grade B). A similar target could be 
considered for pregnant women with preeclampsia (Grade D).  
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3. B. Additional antihypertensive drugs should be used if target BP levels are not achieved with 
standard-dose monotherapy (Grade C).  Add-on drugs should be from a different drug class 
chosen from first-line or second-line options (Grade D). 
 
II. Management of severe hypertension (BP ≥160/110 mm Hg) in pregnancy 
 
Background. In a secondary analysis of the CHIPS trial, BP ≥160/110 mg Hg was associated 
with significantly worse maternal and perinatal outcomes, independent of the development of 
preeclampsia. These included:  increased maternal hospital length of stay >10 days, pregnancy 
loss or need for high-level neonatal care >48 hours, increased risk of preterm birth at <34 and 
<37 weeks gestation, low birth weight (i.e., weight <the 10th percentile), maternal platelets 
<100x 109/L, and elevated maternal liver enzymes.13 The CHIPS trial did not find significant 
difference in the rate of stroke between study arms due to a low event rate (n=1; 0.2% in tight 
arm vs n=0 in less tight arm), as stroke in pregnancy and the immediate postpartum period is a 
relatively uncommon adverse outcome (30 per 100,000 pregnancies).18, 22  Importantly, BP 
≥160/110 mm Hg  and the presence of HDP are both considered risk factors for ischemic and 
hemorrhage stroke in pregnancy.12, 22-23 Specifically, a large US population based study found 
that women with HDP were 5.2 times more likely to be hospitalized for stroke compared with 
pregnant women with normal BP.23  In a case series of 28 women with HDP with stroke in 
pregnancy or early postpartum, immediately prior to the stroke, SBP was recorded as ≥160 mm 
Hg in 95.8% (23/24) and DBP ≥110 mm Hg in 12.5% (3/24) of women.  While no trials included 
in a Cochrane systematic review of the management of severe hypertension in pregnancy directly 
examined the effect of immediate BP lowering on stroke, BP reduction below this threshold of 
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≥160/110 mm Hg is considered to play an important role in the prevention of stroke in pregnancy 
and is recommended.22, 24  Accordingly, severe hypertension is considered an obstetrical 
emergency from maternal and fetal perspectives, which requires immediate in-hospital care and 
urgent antihypertensive therapy (Figure 2).19    
The specific antihypertensive management of severe hypertension is beyond the scope of 
this guideline and requires the involvement of an interdisciplinary team of care providers (i.e., 
obstetrics, maternal fetal medicine and medical specialists as appropriate) in a hospital setting to 
ensure the ongoing well-being of the mother and fetus through frequent assessments, monitoring, 
and delivery planning, as indicated.2 
  
Guidelines 
1. Women with severe hypertension SBP ≥160 or DBP ≥110 mm Hg in pregnancy require urgent 
antihypertensive therapy as it is considered an obstetrical emergency (Grade D).  
 
Summary/Future Directions 
The present guidelines summarize the best available evidence to guide clinicians in the 
management of hypertension in pregnancy and represents three years of work by the 
Hypertension in Pregnancy subgroup with the support of the HCGC and the SOGC. The next 
update for Hypertension Canada’s Guideline is planned for 2020 to allow for optimal 
dissemination of the 2018 Guidelines though literature searches will be continued on an annual 
basis. New evidence identified as being “practice changing” for clinicians (i.e., associated with 
strong reduction in cardiovascular events or mortality; or a substantial reduction in resource 
utilization) will be brought forward for an interim update to ensure timely implementation of 
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important evidence. Priorities identified for the development of new guidelines in 2020 for the 
Hypertension in Pregnancy subgroup include, among others, the development of evidence-based 
guidelines addressing the management of hypertension both in preconception and postpartum 
women.   
 
Implementation 
Implementation and dissemination of the guidelines is a priority for Hypertension 
Canada. Many strategies are employed to reach a variety of providers who care for patients with 
hypertension. Efforts include knowledge exchange forums, targeted educational materials for 
primary care providers and patients, “Train the Trainer” teaching sessions, as well as slide kits 
and summary documents which are freely available online in French and English 
(www.hypertension.ca). Hypertension Canada receives feedback from end-users to continually 
improve guideline processes and content. The Research and Evaluation Committee conducts 
hypertension surveillance studies, and reviews existing Canadian health surveys to identify gaps 
between current and best practices. 
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Table 1. Hypertension in Pregnancy Research – Methodologic Challenges 
1. Definitions of hypertensive disorders of pregnancy (HDP): 
a. Change in definition of hypertension in pregnancy over time. 
b. Variable definition of preeclampsia between studies: 
Restrictive (GHTN ≥ 140/90 mm Hg plus ≥ 300 mg proteinuria in 24 hours). 
             Broad (GHTN ≥ 140/90 mm Hg plus either ≥ 300 mg proteinuria in 24 hours    
             or other end-organ involvement). 
2. Heterogeneity in types of HDP included may differentially impact clinical outcomes: 
a. Variable severity of disease (ranging from GHTN to severe preeclampsia). 
b. Represent different underlying pathophysiology. 
3. Clinical outcomes not cardiovascular events or mortality. 
a. Use of surrogate outcomes. 
4. Small sample sizes. 
5. Short duration of follow-up (hours to months). 
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Table 2.  Antihypertensive medications commonly used in pregnancy 
First Line Oral Drugs 
(Grade C) 
Second Line Oral 
Drugs 
(Grade D) 
Medications to Avoid 
 
Labetalol Clonidine ACEi* (Grade C) 
Methyldopa Hydralazine ARBs* (Grade D) 
Long-acting oral 
nifedipine 
Thiazide diuretics   *fetotoxicity of renal    
    system 
Other β-blockers 
(acebutolol, metoprolol, 
pindolol, & propranolol) 
  
ACEi=angiotension converting enzyme inhibitors 
ARBs=angiotension receptor blockers 
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Figure 1. Simplified Classification of Hypertensive Disorders of Pregnancy 
* Rule out:  White coat hypertension and transient hypertension 
SBP = systolic blood pressure, DBP = diastolic blood pressure 
HELLP = hemolysis elevated liver enzymes and low platelets 
 
 
Figure 2.  Management of Hypertension in Pregnancy                
*See SOGC 2014
2
 
**See Table 2 
BP=blood pressure, DBP=diastolic blood pressure 
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